

Table 1. Demographic, clinical and laboratory characteristics of the 98 newly diagnosed GD patients, according to the presence of IGF1 deficiency

Parameter	All (N=98)	No IGF1 deficiency (N=80)	IGF1 deficiency (N=18)	p
Age at diagnosis median (IQR), (years)	42 (23)	42 (21)	46 (35)	0.680
Current smoker N (%)	33 (33.7)	28 (35)	5 (27.8)	0.558
BMI mean±SD, (kg/m ²)	25.25±6.48	24.49±5.53	28.55±9.07	0.023
Gender N (%)				
Females	78 (79.6)	61 (76.2)	17 (94.4)	0.084
Goiter size N (%)				0.533
Grade 0	3 (3.1)	3 (3.8)	0 (0)	
Grade 1	30 (30.6)	23 (28.7)	7 (38.9)	
Grade 2	65 (66.3)	54 (67.5)	11 (61.1)	
Ophthalmopathy N (%)	24 (24.5)	18 (22.5)	6 (33.3)	0.334
TSH median (IQR), (miu/L)	0.006 (0.010)	0.006 (0.011)	0.005 (0.005)	0.510
FT4 median (IQR), (ng/dl)	3.57 (3.35)	3.35 (3.20)	4.66 (3.18)	0.235
TT3 median (IQR), (ng/ml)	331.16 (293.60)	318.50 (283.00)	417.00 (302.00)	0.168
FT3 median (IQR), (pg/ml)	8.26 (6.30)	7.33(5.72)	11.30 (7.64)	0.027
Thyroglobulin median (IQR), (ng/ml)	25.45 (88.55)	11.40 (80.74)	72.55 (116.02)	0.002
TPOAb median (IQR), (iu/ml)	77.15 (637.62)	234.70(940.25)	57.45 (578.60)	0.270
ATA median (IQR), (iu/ml)	20.00 (51.00)	34.05(161.00)	20.00 (0)	<0.001
TRAb median (IQR), (iu/L)	6.12 (14.45)	8.50 (15.40)	8.51 (32.86)	0.690
HS-CRP median (IQR), (mg/L)	2.00 (5.10)	1.91 (5.07)	2.65 (4.51)	0.388
TNFα median (IQR), (pg/ml)	7.50 (5.12)	7.55 (5.07)	7.50 (5.05)	0.752

Data are presented as percents, mean±SD or median (IQR) according to the type of the variable and the normality of distribution. P value for comparison between GD patients with and without IGF1 deficiency. IGF1 deficiency: IGF1 z score ≤-2 DS.

GD: Graves' disease; N: number of cases; IGF1: Insulin-like growth factor 1; IQR: interquartile range; SD: standard deviation; BMI: body mass index; TSH: thyroid-stimulating hormone; FT4: free thyroxine; FT3: free triiodothyronine; TT3: total triiodothyronine; TPOAb: anti-thyroperoxidase antibodies; ATA: anti-thyroglobulin antibodies; TRAb: thyroid-stimulating hormone receptor antibodies; HS-CRP: high-sensitivity C-reactive protein; TNF alpha: tumor necrosis factor alpha.